STOCK TITAN

[Form 4] INTEGRAL AD SCIENCE HOLDING CORP. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Insider sale under Rule 10b5-1: An officer of Integral Ad Science Holding Corp. (IAS) reported a sale of 3,527 shares of common stock on 10/03/2025 at a sale price of $10.18 per share. After the transaction the reporting person beneficially owned 139,621 shares. The filing states the trades were executed under a Rule 10b5-1 trading plan adopted on 6/12/2025.

The Form 4 was signed by an authorized representative on 10/07/2025. No derivative transactions or other changes in beneficial ownership were reported on this form.

Insider sale under Rule 10b5-1: Un dirigente di Integral Ad Science Holding Corp. (IAS) ha riportato una vendita di 3,527 azioni ordinarie il 10/03/2025 a un prezzo di vendita di $10.18 per azione. Dopo la transazione la persona che deposita beneficial ownership possedeva 139,621 azioni. La dichiarazione indica che le operazioni sono state eseguite secondo un piano di trading Rule 10b5-1 adottato il 6/12/2025.

Il Form 4 è stato firmato da un rappresentante autorizzato il 10/07/2025. Nessuna operazione su derivati o altre modifiche nella proprietà beneficiaria sono state riportate in questo modulo.

Insider sale under Rule 10b5-1: Un funcionario de Integral Ad Science Holding Corp. (IAS) reportó la venta de 3,527 acciones comunes el 10/03/2025 a un precio de venta de $10.18 por acción. Después de la transacción la persona reportante poseía beneficiosamente 139,621 acciones. La presentación indica que las operaciones se realizaron bajo un plan de negociación Rule 10b5-1 adoptado el 6/12/2025.

El Formulario 4 fue firmado por un representante autorizado el 10/07/2025. No se reportaron transacciones derivadas ni otros cambios en la propiedad beneficiaria en este formulario.

Rule 10b5-1에 따른 내부자 매매: Integral Ad Science Holding Corp. (IAS)의 임원이 3,527 주의 보통주를 10/03/2025에 매도했고 매도 가격은 주당 $10.18입니다. 거래 후 보고자는 유익하게 139,621 주를 소유하게 되었습니다. 제출서는 거래가 Rule 10b5-1 거래 계획에 따라 6/12/2025에 채택되었다고 명시합니다.

Form 4는 10/07/2025에 승인된 대리인이 서명했습니다. 이 양식에는 파생상품 거래나 유익한 소유권의 다른 변경은 보고되지 않았습니다.

Vente par un initié conformément à la règle 10b5-1 : Un dirigeant de Integral Ad Science Holding Corp. (IAS) a déclaré la vente de 3 527 actions ordinaires le 10/03/2025 au prix de vente de $10.18 par action. Après la transaction, la personne déclarant détenait bénéfiement 139,621 actions. Le dépôt indique que les transactions ont été exécutées dans le cadre d'un plan de trading Rule 10b5-1 adopté le 6/12/2025.

Le Formulaire 4 a été signé par un représentant autorisé le 10/07/2025. Aucune transaction sur dérivés ou autre changement de propriété bénéficiaire n'a été signalée sur ce formulaire.

Insiderenverkauf gemäß Regel 10b5-1: Ein Beauftragter von Integral Ad Science Holding Corp. (IAS) meldete den Verkauf von 3.527 Stammaktien am 10/03/2025 zu einem Verkaufspreis von $10.18 pro Aktie. Nach der Transaktion besaß die meldende Person wirtschaftlich 139,621 Aktien. Der Einreichung zufolge wurden die Trades im Rahmen eines Rule 10b5-1-Handelsplans durchgeführt, der am 6/12/2025 angenommen wurde.

Das Formular 4 wurde von einem autorisierten Vertreter am 10/07/2025 unterschrieben. Keine Derivate-Geschäfte oder andere Veränderungen des wirtschaftlichen Eigentums wurden in diesem Formular gemeldet.

بيع داخلي وفق القاعدة 10b5-1: أبلغ موظف في Integral Ad Science Holding Corp. (IAS) عن بيع 3,527 سهمًا من الأسهم العادية في 10/03/2025 بسعر بيع قدره $10.18 للسهم. بعد الصفقة امتلك المبلّغ نيابةً عن نفسه 139,621 سهمًا. يذكر الإيداع أن التداولات تمت بموجب خطة تداول Rule 10b5-1 المعتمدة في 6/12/2025.

تم توقيع النموذج 4 من قبل ممثل مخوّل في 10/07/2025. لم ترد أية معاملات مشتقة أو تغييرات أخرى في الملكية المستفيدة في هذا النموذج.

根据规则10b5-1的内部人交易: Integral Ad Science Holding Corp.(IAS)的一名高管报告在10/03/2025以每股$10.18的价格出售了共计3,527股普通股。交易后,申报人实际拥有139,621股股份。该备案称交易是根据于6/12/2025通过的Rule 10b5-1交易计划执行的。

Form 4由一名授权代表在10/07/2025签署。该表格未报告派生品交易或其他在受益所有权方面的变动。

Positive
  • Sale executed under Rule 10b5-1, indicating a pre-established trading plan adopted on 6/12/2025
  • Modest reduction of holdings: only 3,527 shares sold leaving 139,621 shares
Negative
  • No negative points disclosed in the filing; no derivatives or other material changes reported

Insights

Officer sale executed under a pre-established 10b5-1 plan; modest share reduction.

The reported sale of 3,527 shares at $10.18 reduced the officer's direct holdings to 139,621 shares. Using a Rule 10b5-1 plan indicates the transactions were pre-programmed and intended to provide an affirmative defense against insider trading claims.

Dependency and risk center on the plan's terms and timing; confirm whether the plan includes periodic sales or was a one-off. Near-term items to watch include any additional Form 4 filings that would show follow-up transactions or plan termination.

Insider sale under Rule 10b5-1: Un dirigente di Integral Ad Science Holding Corp. (IAS) ha riportato una vendita di 3,527 azioni ordinarie il 10/03/2025 a un prezzo di vendita di $10.18 per azione. Dopo la transazione la persona che deposita beneficial ownership possedeva 139,621 azioni. La dichiarazione indica che le operazioni sono state eseguite secondo un piano di trading Rule 10b5-1 adottato il 6/12/2025.

Il Form 4 è stato firmato da un rappresentante autorizzato il 10/07/2025. Nessuna operazione su derivati o altre modifiche nella proprietà beneficiaria sono state riportate in questo modulo.

Insider sale under Rule 10b5-1: Un funcionario de Integral Ad Science Holding Corp. (IAS) reportó la venta de 3,527 acciones comunes el 10/03/2025 a un precio de venta de $10.18 por acción. Después de la transacción la persona reportante poseía beneficiosamente 139,621 acciones. La presentación indica que las operaciones se realizaron bajo un plan de negociación Rule 10b5-1 adoptado el 6/12/2025.

El Formulario 4 fue firmado por un representante autorizado el 10/07/2025. No se reportaron transacciones derivadas ni otros cambios en la propiedad beneficiaria en este formulario.

Rule 10b5-1에 따른 내부자 매매: Integral Ad Science Holding Corp. (IAS)의 임원이 3,527 주의 보통주를 10/03/2025에 매도했고 매도 가격은 주당 $10.18입니다. 거래 후 보고자는 유익하게 139,621 주를 소유하게 되었습니다. 제출서는 거래가 Rule 10b5-1 거래 계획에 따라 6/12/2025에 채택되었다고 명시합니다.

Form 4는 10/07/2025에 승인된 대리인이 서명했습니다. 이 양식에는 파생상품 거래나 유익한 소유권의 다른 변경은 보고되지 않았습니다.

Vente par un initié conformément à la règle 10b5-1 : Un dirigeant de Integral Ad Science Holding Corp. (IAS) a déclaré la vente de 3 527 actions ordinaires le 10/03/2025 au prix de vente de $10.18 par action. Après la transaction, la personne déclarant détenait bénéfiement 139,621 actions. Le dépôt indique que les transactions ont été exécutées dans le cadre d'un plan de trading Rule 10b5-1 adopté le 6/12/2025.

Le Formulaire 4 a été signé par un représentant autorisé le 10/07/2025. Aucune transaction sur dérivés ou autre changement de propriété bénéficiaire n'a été signalée sur ce formulaire.

Insiderenverkauf gemäß Regel 10b5-1: Ein Beauftragter von Integral Ad Science Holding Corp. (IAS) meldete den Verkauf von 3.527 Stammaktien am 10/03/2025 zu einem Verkaufspreis von $10.18 pro Aktie. Nach der Transaktion besaß die meldende Person wirtschaftlich 139,621 Aktien. Der Einreichung zufolge wurden die Trades im Rahmen eines Rule 10b5-1-Handelsplans durchgeführt, der am 6/12/2025 angenommen wurde.

Das Formular 4 wurde von einem autorisierten Vertreter am 10/07/2025 unterschrieben. Keine Derivate-Geschäfte oder andere Veränderungen des wirtschaftlichen Eigentums wurden in diesem Formular gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gil Alexis II

(Last) (First) (Middle)
C/O INTEGRAL AD SCIENCE HOLDING CORP.
12 E. 49TH STREET, 20TH FLOOR

(Street)
NEW YORK NY 10017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INTEGRAL AD SCIENCE HOLDING CORP. [ IAS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.001 par value 10/03/2025 S 3,527(1) D $10.18 139,621 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Such Rule 10b5-1 trading plan was adopted by the Reporting Person on June 12, 2025.
Remarks:
/s/ Yossi Almani, by Power of Attorney 10/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IAS insider Gil Alexis II report on Form 4?

The officer reported a sale of 3,527 shares of IAS common stock on 10/03/2025 at $10.18 per share, leaving 139,621 shares beneficially owned.

Was the sale part of a 10b5-1 trading plan for IAS insider filings?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 6/12/2025.

Did the Form 4 report any option exercises or derivative transactions for IAS?

No. Table II (derivative securities) shows no transactions or holdings reported on this Form 4.

When was the Form 4 signed and filed?

The signature block shows the form was signed by a representative on 10/07/2025.

How many shares does the reporting person hold after the sale?

The reporting person beneficially owned 139,621 shares following the reported transaction.
Integral Ad Science Holding Corp.

NASDAQ:IAS

IAS Rankings

IAS Latest News

IAS Latest SEC Filings

IAS Stock Data

1.70B
100.31M
0.94%
97.72%
3.52%
Advertising Agencies
Services-computer Programming, Data Processing, Etc.
Link
United States
NEW YORK